Detailed answers about C&M CLINICAL ENGINEERING SOLUTIONS LTD, including incorporation, status, business activity, and accounts information.
When was C&M CLINICAL ENGINEERING SOLUTIONS LTD founded?
C&M CLINICAL ENGINEERING SOLUTIONS LTD was officially incorporated on 26 May 2020 and is registered under company number 12621076. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is C&M CLINICAL ENGINEERING SOLUTIONS LTD?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of C&M CLINICAL ENGINEERING SOLUTIONS LTD?
C&M CLINICAL ENGINEERING SOLUTIONS LTD's current status is Active - Proposal to Strike off. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does C&M CLINICAL ENGINEERING SOLUTIONS LTD do?
C&M CLINICAL ENGINEERING SOLUTIONS LTD operates in the following sectors: 33130 - Repair of electronic and optical equipment, 33190 - Repair of other equipment. These SIC codes provide insight into the company's business activities and industry focus.
What is C&M CLINICAL ENGINEERING SOLUTIONS LTD's registered address?
The registered office address of C&M CLINICAL ENGINEERING SOLUTIONS LTD is PO Box 4385, 12621076 - COMPANIES HOUSE DEFAULT ADDRESS, CARDIFF, CF14 8LH. This is the official address filed with Companies House for legal and statutory correspondence.
Is C&M CLINICAL ENGINEERING SOLUTIONS LTD financially stable?
The most recent accounts for C&M CLINICAL ENGINEERING SOLUTIONS LTD were made up to 24 May 2023, filed as DORMANT. Next accounts are due by 28 February 2025.